Radionuclide therapy in advanced prostate cancer: from pain killer to disease modifier and beyond

Read full text Summarise with VIRAT
Authors: Joseph O'Sullivan
Cited by: 0

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

The use of radionuclide therapy in prostate cancer has been a key focus of my research over the past 22 years. During that time, the use of radionuclide therapy in the treatment of metastatic disease has steadily increased. The initial wave of radionuclides used in prostate cancer were based on the classical prostate cancer phenotype of bone forming metastases which facilitated bone-targeted therapies such as Strontium-89 and Samarium-153 EDTMP. These agents were effective at reducing pain however there was no disease modifying benefit. In the past 10 years (the time frame for the papers discussed in this critical analysis) my research has involved innovative clinical trials of combination of Rhenium-186 HEDP with chemotherapy, dosimetry studies of Rhenium-186, large trials developing Radium-223 as a life prolonging therapy, and a first ever trial of Radium-223 in metastatic castration sensitive prostate cancer. I believe that my work in radionuclide therapy in advanced prostate cancer has made an important contribution to keeping the field vibrant. The next wave of radionuclide therapies in prostate cancer are focused on a cell surface protein called Prostate Specific Membrane Antigen (PSMA) are already showing the potential for life-extension in advanced prostate cancer. For copyright reasons this thesis is partially redacted.

Fields of Study & Subjects

Radiopharmaceutical Chemistry and Applications Prostate Cancer Treatment and Research Prostate Cancer Diagnosis and Treatment

Publication details

Journal / source
Research Portal (Queen's University Belfast)
Publication date
1 October 2026
Language
EN
Document type
Thesis